Sleep Disorders in Perimenopausal Women and
Metabolic Syndrome, is that True?
Volume 1 - Issue 2
Pilnik Susana*, Belardo Maria Alejandra, Cavanna Malena, De Nardo Barbara and Starvaggi Agustina
-
Author Information
Open or Close
- Department of Gynecology, Italiano de Buenos Aires Hospital, Argentina
*Corresponding author:
Pilnik Susana, Department of Gynecology, Italiano de Buenos Aires Hospital, Argentina
Received: June 22, 2018; Published: July 02, 2018
DOI: 10.32474/OAJRSD.2018.01.000109
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Sleep disorders (SD) are a common complaint in women going through menopause transition. It is well known that there is
a close relationship between SD and one of the main menopausal symptoms: vasomotor symptoms (VMS). To acknowledge this
association is essential when investigating menopausal transition and SD. The Study of Women’s Health across the Nation (SWAN),
shows that the prevalence of sleep disturbance increases with age. The prevalence in perimenopausal and postmenopausal women
varies from 39% to 47% and 35% to 60% respectively. Although both menopausal transition and aging increase sleep disturbances,
etiology in menopausal women is probably multifactorial. A decline in the levels of reproductive hormones and melatonin, and
the complex interaction among these hormones can significantly contribute to sleep problems, poor concentration, fatigue and
decreased quality of life. On the one hand menopause nearly adversely affects all components of metabolic syndrome (MS) and on
the other hand the cumulative long-term effects of deprived sleep have been associated with many cardio metabolic consequences
including hypertension, obesity, and impaired glucose metabolism. Management strategies should be taken into account to help
women ameliorate their night sleep, in order to prevent future complications and to improve their quality of life (QoL).
Keywords: Sleep disorders; Menopause; Vasomotor symptoms; Metabolic syndrome
Abbreviations: SD: Sleep Disorders; VMS: Vasomotor Symptoms; SWAN: Study of Women’s Health Across the Nation; MS: Metabolic
Syndrome; QoL: Quality of Life; OSA: Obstructive Sleep Apnea; FSH: Follicle Stimulating Hormone; IR: Insulin Resistance; DBT: Type-
2 Diabetes; CVD: Cardio Vascular Disease; HPA: Hypothalamus-Pituitary-Adrenal; AHI: Apnea Hypopnea Index; GABA: Gamma-
Amino Butyric Acid;
Abstract|
Introduction|
Treatment|
Conclusion|
References|